



US009192621B2

(12) **United States Patent**  
Mayes et al.

(10) **Patent No.:** US 9,192,621 B2  
(45) **Date of Patent:** Nov. 24, 2015

- (54) **ESTERS AND MALONATES OF SATE PRODRUGS**
- (71) Applicant: **IDENIX PHARMACEUTICALS LLC**, Cambridge, MA (US)
- (72) Inventors: **Benjamin Alexander Mayes**, Boston, MA (US); **Adel M. Moussa**, Burlington, MA (US)
- (73) Assignee: **IDENIX PHARMACEUTICALS LLC**, Cambridge, MA (US)
- (\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

6,573,247 B1	6/2003	McGuigan et al.
6,608,191 B1	8/2003	Anderson et al.
6,638,919 B2	10/2003	McGuigan et al.
6,660,721 B2	12/2003	Devos et al.
6,777,395 B2	8/2004	Bhat et al.
6,784,161 B2	8/2004	Ismaili et al.
6,784,166 B2	8/2004	Devos et al.
6,833,361 B2	12/2004	Hong et al.
6,846,810 B2	1/2005	Martin et al.
6,911,424 B2	6/2005	Schinazi et al.
6,914,054 B2	7/2005	Sommadossi et al.
6,927,291 B2	8/2005	Jin et al.
6,995,146 B2	2/2006	Anderson et al.
7,018,989 B2	3/2006	McGuigan et al.
7,019,135 B2	3/2006	McGuigan et al.
7,094,770 B2	8/2006	Watanabe et al.
7,105,493 B2	9/2006	Sommadossi et al.
7,105,499 B2	9/2006	Carroll et al.
7,115,590 B1	10/2006	Daluge et al.

(Continued)

- (21) Appl. No.: **14/038,617**
- (22) Filed: **Sep. 26, 2013**

## FOREIGN PATENT DOCUMENTS

- (65) **Prior Publication Data**  
US 2014/0086873 A1 Mar. 27, 2014

CN	1133642 C	1/2004
CN	103848876 A	6/2014

(Continued)

**Related U.S. Application Data**

- (60) Provisional application No. 61/706,616, filed on Sep. 27, 2012.

U.S. Appl. No. 11/005,443, filed Dec. 6, 2004, LaColla et al.  
U.S. Appl. No. 14/146,520, filed Jan. 2, 2014, Storer et al.  
International Search Report and Written Opinion in PCT/US2013/061991, mailed Nov. 4, 2013, 9 pages.  
Congiatu et al., Novel Potential Anticancer Naphthyl Phosphoramidates of BVdU: Separation of Diastereoisomers and Assignment of the Absolute Configuration of the Phosphorus Center (2006) *Journal of Medicinal Chemistry* 49:452-455.

(Continued)

- (51) **Int. Cl.**  
*C07H 19/10* (2006.01)  
*C07H 19/20* (2006.01)  
*A61K 31/7076* (2006.01)  
*C07H 17/02* (2006.01)  
*A61K 45/06* (2006.01)  
*C07H 19/16* (2006.01)  
*A61K 31/403* (2006.01)  
*A61K 31/497* (2006.01)  
*A61K 31/7056* (2006.01)  
*A61K 31/708* (2006.01)  
*A61K 38/21* (2006.01)

*Primary Examiner* — Traviss C McIntosh, III  
(74) *Attorney, Agent, or Firm* — Squire Patton Boggs (US) LLP

- (52) **U.S. Cl.**  
CPC ..... *A61K 31/7076* (2013.01); *A61K 31/403* (2013.01); *A61K 31/497* (2013.01); *A61K 31/708* (2013.01); *A61K 31/7056* (2013.01); *A61K 38/212* (2013.01); *A61K 45/06* (2013.01); *C07H 17/02* (2013.01); *C07H 19/10* (2013.01); *C07H 19/16* (2013.01); *C07H 19/20* (2013.01)


**ABSTRACT**

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other antiviral agents. In certain embodiments, provided herein are compounds according to Formula 1001:

- (58) **Field of Classification Search**  
None  
See application file for complete search history.

(1001)

- (56) **References Cited**  
U.S. PATENT DOCUMENTS



or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Y, Z, A, R<sup>C</sup> and R<sup>D</sup> are as described herein.

3,480,613 A	11/1969	Walton et al.
6,174,868 B1	1/2001	Anderson et al.
6,284,458 B1	9/2001	Anderson et al.
6,348,587 B1	2/2002	Schinazi et al.
6,391,542 B1	5/2002	Anderson et al.
6,423,489 B1	7/2002	Anderson et al.
6,433,159 B1	8/2002	Anderson
6,455,513 B1	9/2002	McGuigan et al.
6,566,365 B1	5/2003	Storer

**22 Claims, No Drawings**